Division of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada.
Na Homolce Hospital, Prague, Czech Republic.
Neurosurgery. 2019 Oct 1;85(4):535-542. doi: 10.1093/neuros/nyy416.
Stereotactic radiosurgery (SRS) is a highly effective management approach for patients with vestibular schwannomas (VS), with 10-yr control rates up 98%. When it fails, however, few data are available to guide management.
To perform a retrospective analysis of patients who underwent 2 SRS procedures on the same VS to assess the safety and efficacy of this practice.
This study was opened to centers of the International Gamma Knife Research Foundation (IGKRF). Data collected included patient characteristics, clinical symptoms at the time of SRS, radiosurgery dosimetric data, imaging response, clinical evolution, and survival. Actuarial analyses of tumor responses were performed.
Seventy-six patients from 8 IGKRF centers were identified. Median follow-up from the second SRS was 51.7 mo. Progression after the first SRS occurred at a median of 43 mo. Repeat SRS was performed using a median dose of 12 Gy. Actuarial tumor control rates at 2, 5, and 10 yr following the second SRS were 98.6%, 92.2%, and 92.2%, respectively. Useful hearing was present in 30%, 8%, and 5% of patients at first SRS, second SRS, and last follow-up, respectively. Seventy-five percent of patients reported stable or improved symptoms following the second SRS. Worsening of facial nerve function attributable to SRS occurred in 7% of cases. There were no reports of radionecrosis, radiation-associated edema requiring corticosteroids, radiation-related neoplasia, or death attributable to the repeat SRS procedure.
Patients with progressing VS after radiosurgery can be safely and effectively managed using a second SRS procedure.
立体定向放射外科(SRS)是一种治疗前庭神经鞘瘤(VS)的非常有效的方法,10 年控制率高达 98%。然而,当它失败时,几乎没有数据可以指导治疗。
对同一 VS 接受 2 次 SRS 治疗的患者进行回顾性分析,以评估这种治疗方法的安全性和有效性。
本研究对国际伽玛刀研究基金会(IGKRF)的中心开放。收集的数据包括患者特征、SRS 时的临床症状、放射外科剂量学数据、影像学反应、临床演变和生存情况。对肿瘤反应进行了累积分析。
从 8 个 IGKRF 中心确定了 76 名患者。第二次 SRS 后的中位随访时间为 51.7 个月。第一次 SRS 后进展发生于中位数为 43 个月。重复 SRS 使用中位数剂量 12 Gy。第二次 SRS 后 2、5 和 10 年的肿瘤控制率分别为 98.6%、92.2%和 92.2%。第一次 SRS、第二次 SRS 和最后一次随访时,有听力的患者分别为 30%、8%和 5%。第二次 SRS 后,75%的患者报告症状稳定或改善。由于 SRS 导致的面神经功能恶化发生在 7%的病例中。没有报告与重复 SRS 程序相关的放射性坏死、需要皮质类固醇的放射性相关水肿、放射性相关肿瘤或死亡。
对于放射外科后进展的 VS 患者,可以安全有效地使用第二次 SRS 治疗。